Sbir phase II: novel hyaluronan enhanced polymeric trans-catheter aortic valve
Active Project Grant Awarded Last action
- Award ID
- R44HL158387
- Recipient
-
Youngheartvalve, Inc. UEI KDSXAGSGZGV1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,169,794
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 88% complete
- Originally
- Place of performance
- Atlanta, GA 30313, USA
Award details come from USAspending.gov.
Description
- Abstract
- Youngheartvalve (YHV), INC. Is commercializing the rejuvenate™ heart valve, a balloon-expandable, stented, transcatheter aortic heart valve (tavr) with hyaluronan-impregnated polymeric, flexible leaflets that will obviate the need for chronic anti-coagulation and prevent calcification while simultaneously rivaling the longevity of surgically placed mechanical valves. Unique and novel dynamic sealing technology (DST) that activates once implanted will form fit the valve to provide for a more complete and reliable annular seal, rivaling that of sutured-in-place surgical valves. Further, YHV's "no tissue / no farm" manufacturing automation and supply chain will significantly reduce the cost and complexity of today's pericardial based tavr systems, thereby opening up possibilities for this life-saving technology to truly be adopted worldwide. Aim 1 will verify valve 2.0 design meets all ISO standards and begin manufacturing for scale up. Aim 2 will complete acute and chronic animal testing to achieve design freeze (valve 3.0). This sbir phase II grant will help YHV emerge from the "valley of death" commonly faced by start-UPS. The rejuvenate™ valve will be ready for GLP pre-clinical testing and "first-in-human" testing. YHV will have the supply-chain, manufacturing, and distribution relationships required for commercialization, will have raised "series a" funding in parallel with phase II funding and have a full-time employee team. Youngheartvalve, INC. Was CO-founded by DRS. Dasi (chief technology officer) and james (chief operating officer), based on technology they jointly developed over the preceding decade with NIH funding. MR. Todd tomba, youngheartvalve CEO and president, brings over three decades of medical device industry, specifically heart valve replacement commercialization experience, to the team. MS. Arthi rathi, youngheartvalve CFO, a CPA by professional background, brings over a decade of healthcare financial leadership experience to YHV. Our scientific advisory board consists of key opinion leaders and pioneers in the field of heart valves: DR. Vinod thourani (piedmont hospital, president of heart valve society), howard hermann (professor of cardiovascular medicine, u. Penn) and DR. Janarthanan sathananthan (director of the centre for heart valve innovation bench testing laboratory, u. British columbia). Youngheartvalve is currently being incubated within georgiatech's venturelab with lab space in the gatv innovation labs.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $1,518,670 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,325,562 | |
| Original award | $1,325,562 |
Quick answers
Who received award R44HL158387?
R44HL158387 was awarded to Youngheartvalve, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 17, 2021.
How much is award R44HL158387 worth?
$4,169,794 has been obligated on R44HL158387.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award